The Food and Drug Administration’s efforts to speed approvals of drugs to fight antibiotic-resistant bacteria will be front and center Monday as the agency considers two new antibiotics with possible advantages. Aaron S. Kesselheim, assistant professor of medicine at Brigham and Women’s Hospital, is quoted.
Read full article (subscription required)
